2022 SPIE and Photonics Media Prism Awards Celebrate Innovative Photonics Technologies
27.1.2022 09:10:00 EET | Business Wire | Press release
Earlier this evening, following a festive reception during SPIE Photonics West, SPIE, the international society for optics and photonics, and Photonics Media recognized the top optics and photonics products on the market with their industry-focused Prism Awards.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220126005964/en/
2022 SPIE and Photonics Media Prism Awards celebrate innovative photonics technologies at SPIE Photonics West. (Graphic: Business Wire)
The 14th annual ceremony showcased a dynamic range of companies — from Luxexcel, PlenOptika, and Lumotive, to SWIR, LightPath Technologies, and ColdQuanta — applying innovative and creative solutions to critical problems in areas such as augmented and virtual reality, biomedical devices, autonomous vehicles, quantum, and industrial lasers. In addition, the 2021 Prism Award winners of last year’s virtual ceremony were recognized in person at the beginning of the program.
Each year, the Prism Awards reflect the latest exciting developments, exponential growth, and rich technical innovations across photonics and photonics-enabled industries. For consideration in this year's awards, SPIE received 120 applications from 18 countries.
Finalists and winners were selected by a panel of international judges who leveraged the knowledge and acumen of leaders from across the technology commercialization and funding sectors. The distinguished judges’ roster included MKS Instruments’ Marc D. Himel, the FDA’s Zane Arp, Femto Blanc’s Uri Abrams, iFocus’ Adi Diner, Berkeley Catalyst Fund’s Laura Smoliar, Engender Technologies’ Cather Simpson, Luminate Accelerator’s Sujatha Ramanujan, Notal Vision’s Nishant Mohan, Teledyne Princeton Instruments’ Jason McClure, and Chromacity’s Shahida Imani.
"We are particularly delighted to be celebrating our Prism Award winners in person this year,” said SPIE CEO Kent Rochford. "These companies with their scientists and engineers — and I am including the award finalists as well — are ensuring that key technologies and products are reaching, energizing, and continually growing the photonics market. Their critical, innovative work is impacting lives across the globe.”
"Each year, the Prism Awards singles out the very brightest innovations in a highly innovative industry and, despite a global pandemic, supply chain issues, and other challenges over the past year, the 2022 winners still found a way to advance the field of photonics in important and remarkable ways,” said President and CEO of Photonics Media Tom Laurin. “We extend our congratulations to each of this year’s winners, who deserve our industry's recognition for their advancements in transportation, biomedicine, research, sensing, and quantum technology."
Below is the complete list of the award categories and the winners:
- Augmented & Virtual Reality: Luxexcel
- Autonomous Vehicles: Lumotive
- Better Sensing: SWIR Vision Systems
- Biomedical Devices: PlenOptika
- Displays: BRELYON
- Industrial Lasers: Civan Lasers
- Manufacturing & Test: LightPath Technologies
- Quantum: ColdQuanta
- Scientific Lasers: Stuttgart Instruments
- Software: Zemax
To find out more about the Prism Awards, please visit our website.
About Photonics Media
Photonics Media publishes print and digital business-to-business magazines, buyers' guides, websites, e-newsletters, webinars, virtual conferences, and podcasts for individuals working with light-based technologies in the photonics industry. A pioneering publisher in the discipline of photonics, Photonics Media has built a large global audience comprising academics and researchers, manufacturers, and end-users. Over the past six decades, the company has fostered a tradition of innovation that has defined the industry. As its publications grow — following the technology into an ever-widening range of applications — the company adheres to a philosophy of editorial quality and integrity, maintaining an international reputation for leadership in photonics. www.photonics.com.
About SPIE
SPIE, the international society for optics and photonics, brings engineers, scientists, students, and business professionals together to advance light-based science and technology. The Society, founded in 1955, connects and engages with our global constituency through industry-leading conferences and exhibitions; publications of conference proceedings, books, and journals in the SPIE Digital Library; and career-building opportunities. Over the past five years, SPIE has contributed more than $22 million to the international optics community through our advocacy and support, including scholarships, educational resources, travel grants, endowed gifts, and public-policy development. www.spie.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220126005964/en/
Contact information
Daneet Steffens
Public Relations Manager
daneets@spie.org
+1 360 685 5478
@SPIEtweets
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom